Abstract
Radiation therapy (RT) causes inflammation, activation of pro-fibrotic cytokines, and endothelial and microvascular damage. Radiation increases oxidative stress through free radical production and results in recruitment of matrix metalloproteinases and pro-inflammatory mediators. These changes may lead to acute toxicity (evident during or shortly after radiotherapy) and start a chronic process leading to delayed dysfunction that is evident several years later. Acute changes largely result from direct radiation damage and the immediate inflammatory response, while long-term changes are due to stem cell loss and late and persistent tissue fibrosis. Thus, chronic radiation-induced damage is irreversible and can affect multiple cardiac structures including the coronary arteries, myocardium, pericardium, cardiac valves, and the conduction system. The incidence of acute pericarditis has decreased over time from 20 % to 2.5 % with modern radiation techniques; therapy is the same as for acute viral or idiopathic pericarditis. Ventricular dysfunction is a rare event. It is more frequent when an anthracycline or high-dose chemotherapy is administered concurrently, or shortly before RT, since radiation interacts synergistically to induce myocardial damage.Delayed radiation-induced heart disease (RIHD) is a significant problem, especially in long-term survivors of lymphoma and breast cancer. The median time from RT to appearance of clinically significant RIHD is 15 years, with the incidence increasing progressively over time. All the patients treated with mediastinal or chest radiotherapy more than 10 years ago should be object of an active program of prevention and follow-up. The follow-up should last lifelong. Many cancer patients who achieved complete remission are dismissed by the oncological follow-up after 5–10 years. Few patients have the opportunity to be included in a cancer survivor clinic for long-term follow-up of treatment-related disease. The general practitioners and the cardiologists should take care of this problem. The group at highest risk is represented by childhood cancer survivors, and this problem has been addressed in Chap. 16. Coronary Artery Disease (CAD) is the most frequent and relevant form of RIHD. The risk of death due to acute myocardial infarction (AMI) is two- to fourfold higher in patients treated for Hodgkin lymphoma compared with age-matched controls, but can be increased sevenfold or higher in some subgroups. The mechanism involved in plaque formation is thought to mirror spontaneous atherosclerosis; however, plaques in irradiated patients have been found to be more fibrous with decreased lipid content, and the lesions are consistently more proximal, smoother, concentric, tubular, and longer. Left ventricular (LV) dysfunction is a frequent complication of chest RT, and may be due to: macroscopic CAD leading to chronic ischemia; decrease in capillary density resulting in myocyte hypoxia; direct myocyte damage and necrosis, more evident in synergy with anthracycline cardiotoxicity, with progressive fibrosis replacing viable myocardial tissue; increase in type I collagen rather than type III collagen, leading to reduced myocardial distensibility. Valvular heart disease (VHD) ranges from sclerosis to severe, often calcific, valvular stenosis and/or regurgitation. It is more common after mediastinal RT in comparison to chest wall RT for breast cancer. Among breast cancer patients, it is more common after left-sided RT in comparison to right-sided RT. Chronic pericarditis may develop as a consequence of acute pericarditis seen during or shortly after RT and as a delayed complication. Most patients have a combination of restrictive and constrictive disease and pericardial stripping does not afford similar benefits in RT patients compared to those with constriction due to other causes. Arrhythmias can be seen as a consequence of RT, and may be both hyperkinetic and hypokinetic. Inappropriate sinus tachycardia, both at rest and during effort, is common after thoracic RT and is felt to be a consequence of autonomic dysfunction. Bundle branch and atrio-ventricular blocks may also be observed. Radiation-induced carotid disease produces carotid lesions that are more extensive than the traditional bifurcation stenosis and often involves atypical areas such as long segments of the carotid artery. The global risk of cerebrovascular events is increased and the common atherosclerosis risk factors and preexisting atherosclerotic lesions are exacerbating factors In patients presenting with symptoms of dyspnea, fatigue, and reduced exercise tolerance, it is important to consider other organs that may be affected by RT or chemotherapy in the differential diagnosis: acute, chronic and recall radiation pneumonitis should be ruled out; chemotherapyinduced lung disease may be observed with several agents, mostly with bleomycin; radiation fields including the neck (such as mantle field used for HL) may cause thyroid dysfunction, most frequently hypothyroidism..
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front Oncol. 2015;5:39.
Murthy SC, Rozas MS, Adelstein DJ, et al. Induction chemoradiotherapy increases pleural and pericardial complications after esophagectomy for cancer. J Thorac Oncol. 2009;4:395–403.
Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant. 2001;28:283–7.
de Ville de Goyet M, Brichard B, et al. Prospective cardiac MRI for the analysis of biventricular function in children undergoing cancer treatments. Pediatr Blood Cancer. 2015;62:867–74.
Marks LB, Yu X, Prosnitz RG, et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005;63(1):214–23.
Gayed I, Gohar S, Liao Z, et al. The clinical implications of myocardial perfusion abnormalities in patients with esophageal or lung cancer after chemoradiation therapy. Int J Cardiovasc Imaging. 2009;25:487–95.
Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117:412–8.
Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98.
Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol. 2003;45:55–75. Review.
Gaya AM, Ashford RF. Cardiac complications of radiation therapy. Clin Oncol (R Coll Radiol). 2005;17:153–9. Review.
van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175:1007–17.
Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99:206–14.
Duma MN, Molls M, Trott KR. From heart to heart for breast cancer patients-cardiovascular toxicities in breast cancer radiotherapy. Strahlenther Onkol. 2014;190:5–7.
Daniëls LA, Krol AD, de Graaf MA, et al. Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptance†. Ann Oncol. 2014;25:1198–203.
Heidenreich PA, Hancock SL, Vagelos RH, et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005;150:977–82.
McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011;100:167–75.
Cella L, Liuzzi R, Conson M, et al. Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin’s lymphoma. Radiother Oncol. 2011;101:316–32.
Wethal T, Lund MB, Edvardsen T, et al. Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer. 2009;101:575–81.
Handa N, McGregor CG, Danielson GK, et al. Valvular heart operation in patients with previous mediastinal radiation therapy. Ann Thorac Surg. 2001;71:1880–4.
Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55:1145–52.
Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015;107(4)
Groarke JD, Tanguturi VK, Hainer J, et al. Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. J Am Coll Cardiol. 2015;65:573–83.
Slama MS, Le Guludec D, Sebag C, et al. Complete atrioventricular block following mediastinal irradiation: a report of six cases. Pacing Clin Electrophysiol. 1991;14:1112–8.
Orzan F, Brusca A, Gaita F, et al. Associated cardiac lesions in patients with radiation-induced complete heart block. Int J Cardiol. 1993;39:151–6.
Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003;42:743–9.
Chargari C, Riet F, Mazevet M, et al. Complications of thoracic radiotherapy. Presse Med. 2013;42:e342–51.
Ding X, Ji W, Li J, Zhang X, Wang L. Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer. Radiat Oncol. 2011;6:24.
Levy A, Hollebecque A, Bourgier C, et al. Targeted therapy-induced radiation recall. Eur J Cancer. 2013;49:1662–8.
Limper AH. Chemotherapy-induced lung disease. Clin Chest Med. 2004;25:53–64.
Della Latta V, Cecchettini A, Del Ry S, Morales MA. Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions. Pharmacol Res. 2015;97:122–30.
Hancock SL, Cox RS, McDougall IR. Thyroid Diseases after Treatment of Hodgkin's Disease. N Engl J Med. 1991;325:599–605.
Jereczek-Fossa BA, Alterio D, Jassem J, et al. Radiotherapy-induced thyroid disorders. Cancer Treat Rev. 2004;30:369–84. Review.
Lancellotti P, Nkomo VT, Badano LP, et al.; European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance; American Society of Nuclear Cardiology; Society for Cardiovascular Magnetic Resonance; Society of Cardiovascular Computed Tomography. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14:721–40.
Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol. 2013;61:2319–28.
Heidenreich P, Schnittger I, Strauss H, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol. 2007;25:43–9.
Kupeli S, Hazirolan T, Varan A, et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin's lymphoma. J Clin Oncol. 2010;28:1025–30.
Schwitter J, Arai AE. Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance. Eur Heart J. 2011;32:799–809.
Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012;379:453–60.
Machann W, Beer M, Breunig M, et al. Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2011;79:1117–23.
Pierga J, Maunoury C, Valette H, et al. Follow-up thallium-201 scintigraphy after mantle field radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1993;25:871–6.
Mulrooney DA, Nunnery SE, Armstrong GT, et al. Coronary artery disease detected by coronary computed tomography angiography in adult survivors of childhood Hodgkin lymphoma. Cancer. 2014;120:3536–44.
Grothues F, Smith G, Moon JC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002;90:29–34.
Caudron J, Fares J, Bauer F, Dacher JN. Evaluation of left ventricular diastolic function with cardiac MR imaging. Radiographics. 2011;31:239–59.
Brouwer C, Postma A, Vonk J, et al. Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer. Eur J Cancer. 2011;47:2453–62.
Nagueh S, Appleton C, Gillebert T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10:165–93.
Dickerson JA, Raman SV, Baker PM, Leier CV. Relationship of cardiac magnetic resonance imaging and myocardial biopsy in the evaluation of nonischemic cardiomyopathy. Congest Heart Fail. 2013;19:29–38.
Zurick A, Bolen M, Kwon D, et al. Pericardial delayed hyperenhancement with CMR imaging in patients with constrictive pericarditis undergoing surgical pericardiectomy: a case series with histopathological correlation. JACC Cardiovasc Imaging. 2011;4:1180–91.
Feng D, Glockner J, Kim K, et al. Cardiac magnetic resonance imaging pericardial late gadolinium enhancement and elevated inflammatory markers can predict the reversibility of constrictive pericarditis after antiinflammatory medical therapy: a pilot study. Circulation. 2011;124:1830–7.
Francone M, Dymarkowski S, Kalantzi M, et al. Assessment of ventricular coupling with real-time cine MRI and its value to differentiate constrictive pericarditis from restrictive cardiomyopathy. Eur Radiol. 2006;16:944–51.
Thavendiranathan P, Verhaert D, Walls M, et al. Simultaneous right and left heart real-time, free-breathing CMR flow quantification identifies constrictive physiology. JACC Cardiovasc Imaging. 2012;5:15–24.
Johansen S, Tjessem KH, Fosså K, et al. Dose Distribution in the Heart and Cardiac Chambers Following 4-field Radiation Therapy of Breast Cancer: a Retrospective Study. Breast Cancer (Auckl). 2013;7:41–9.
Tian S, Hirshfield KM, Jabbour SK, et al. Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. Front Oncol. 2014;4:277.
Schömig K, Ndrepepa G, Mehilli J, et al. Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. Catheter Cardiovasc Interv. 2007;70:359–65.
Brown ML, Schaff HV, Sundt TM. Conduit choice for coronary artery bypass grafting after mediastinal radiation. J Thorac Cardiovasc Surg. 2008;136:1167–71.
Ling LH, Oh JK, Schaff HV, et al. Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation. 1999;100:1380–6.
Bertog SC, Thambidorai SK, Parakh K, et al. Constrictive pericarditis: etiology and cause specific survival after pericardiectomy. J Am Coll Cardiol. 2004;43:1445–52.
Crestanello JA, McGregor CG, Danielson GK, et al. Mitral and tricuspid valve repair in patients with previous mediastinal radiation therapy. Ann Thorac Surg. 2004;78:826–31.
Handa N, McGregor CG, Danielson GK, et al. Coronary artery bypass grafting in patients with previous mediastinal radiation therapy. J Thorac Cardiovasc Surg. 1999;117:1136–42.
Uriel N, Vainrib A, Jorde UP, et al. Mediastinal radiation and adverse outcomes after heart transplantation. J Heart Lung Transplant. 2010;29(3):378–81.
Saxena P, Joyce LD, Daly RC, et al. Cardiac transplantation for radiation-induced cardiomyopathy: the Mayo Clinic experience. Ann Thorac Surg. 2014;98:2115–21.
Chang AS, Smedira NG, Chang CL, et al. Cardiac surgery after mediastinal radiation: extent of exposure influences outcome. J Thorac Cardiovasc Surg. 2007;133:404–13.
Wu W, Masri A. Popovic ZBet al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation. 2013;127:1476–85.
Desai MY, Karunakaravel K, Wu W, et al. Pulmonary fibrosis on multidetector computed tomography and mortality in patients with radiation-associated cardiac disease undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2014;148:475.e3–81.
De Bruin ML, Dorresteijn LD, van't Veer MB, et al. Increased risk of stroke and transientischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101(13):928–37.
Plummer C, Henderson RD, O'Sullivan JD, Read SJ. Ischemic stroke and transientischemic attack after head and neck radiotherapy: a review. Stroke. 2011;42:2410–8.
Acker JC. Serial in vivo observation of cerebral vasculature after treatment with a large single fraction of radiation. Radiat Res. 1998;149:350.
Ye J, Rong X, Xiang Y, et al. A study of radiation-induced cerebral vascular injury in nasopharyngeal carcinoma patients with radiation-induced temporal lobe necrosis. PLoS One. 2012;7(8), e42890.
Louis EL, McLoughlin MJ, Wortzman G. Chronic damage to medium and large arteries following irradiation. J Can Assoc Radiol. 1974;25(2):94–104.
Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831–7.
Cheng SW. Carotid stenosis after radiotherapy for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2000;126:517.
Steele SR, Martin MJ, Mullenix PS, et al. Focused high-risk population screening for carotid arterial stenosis after radiation therapy for head and neck cancer. Am J Surg. 2004;187:594–8.
Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv. 2008;72:563–8.
Zagar TM, Marks LB. Breast cancer radiotherapy and coronary artery stenosis: location, location, location. J Clin Oncol. 2012;30:350.
Mousavi N, Nohria A. Radiation-induced cardiovascular disease. Curr Treat Opt Cardiovasc Med. 2013;15:507–17.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Lestuzzi, C., Nohria, A., Asteggiano, R., Vallerio, P. (2017). Radiotherapy: Clinical Aspects and Cardiotoxicity. In: Lestuzzi, C., Oliva, S., Ferraù, F. (eds) Manual of Cardio-oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-40236-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-40236-9_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-40234-5
Online ISBN: 978-3-319-40236-9
eBook Packages: MedicineMedicine (R0)